The benefit from the treatment of hormone-sensitive oligometastatic prostate cancer still remains unknown. There are multiple publications looking into such therapy that has grown significantly in the past 6 years, but unfortunately, we are facing a variety of definitions not only of what is considered “oligometastatic prostate cancer”, but also there is a variety of outcomes that difficult the comparison of the results among the different publications.1,2 To be more specific, regarding the definition of oligometastatic prostate cancer, there are discrepancies regarding the number of lesions, location of the lesions, type of imaging studies used to detect the lesions, among others.1, 3-8 When we talk about outcomes, some consider PSA response, time to start androgen deprivation therapy, disease-free survival, among others, in order to define a measurable outcome.1, 5, 9-12 Considering the previous, we felt a need to try to define the current practice among Urologists and gathered information of what would be considered a true clinical benefit for their patients, what outcomes would make it “worthwhile” to recommend a treatment for oligometastatic prostate cancer.